Protogerou Vassilis, Beshari Sara El, Michalopoulos Efstathios, Mallis Panagiotis, Chrysikos Dimosthenis, Samolis Alexandros A, Stavropoulos-Giokas Catherine, Troupis Theodoros
Department of Anatomy, School of Medicine, National and Kapodistrian University of Athens, M. Asias 21 st, 12462 Athens, Greece.
2nd Urological Department, Attikon Hospital, Medical School of Athens, National and Kapodistrian University, 12462 Athens, Greece.
Medicines (Basel). 2020 Mar 18;7(3):14. doi: 10.3390/medicines7030014.
The current treatment of Erectile Dysfunction (ED) is mainly based on the use of drugs that provide erections shortly after use but they do not really treat the problem. Stem cell therapy is a novel treatment with regenerative properties that can possibly treat erectile dysfunction. Five patients with erectile disease were treated with Adipose-Derived Stem Cells (ADSCs) and Platelet Lysate Plasma (PLP). ADSCs were obtained through abdominal liposuction and PLP was prepared after obtaining blood samples from peripheral veins. Erectile function was evaluated with the International Index of Erectile Function questionnaire (IIEF-5) questionnaire, penile triplex at the 1st, 3rd, 6th and 12th month post-treatment. A CT scan of the head, thorax and abdomen was done before treatment and at the 12th month. IIEF-5 scores were improved in all patients at the 6th month although not in the same pattern in all patients. Peak Systolic Velocity (PSV) also improved at the 6th month in all patients but also with different patterns in each patient, while End Diastolic Velocity (EDV) was more variable. Two patients decreased the treatment they used in order to obtain erection (from Intracavernosal injections (ICI) they used PDE-5Is), two had unassisted erections and one had an initial improvement which decreased at the 6th month. There were no side effects noted. Stem cell therapy in combination with PLP appears to show some improvement in erectile function and has minimal side effects in the short term.
目前勃起功能障碍（ED）的治疗主要基于使用能在用药后短时间内促使勃起的药物，但这些药物并未真正解决问题。干细胞疗法是一种具有再生特性的新型治疗方法，有可能治疗勃起功能障碍。五名勃起功能障碍患者接受了脂肪来源干细胞（ADSCs）和血小板裂解物血浆（PLP）治疗。ADSCs通过腹部抽脂获取，PLP在从外周静脉采集血样后制备。在治疗后第1、3、6和12个月，使用国际勃起功能指数问卷（IIEF-5）以及阴茎三联检查评估勃起功能。治疗前和第12个月进行头部、胸部和腹部的CT扫描。所有患者在第6个月时IIEF-5评分均有所改善，尽管并非所有患者的改善模式相同。所有患者在第6个月时收缩期峰值流速（PSV）也有所改善，但每位患者的改善模式也不同，而舒张末期流速（EDV）变化更大。两名患者减少了用于勃起的治疗药物（从使用阴茎海绵体内注射（ICI）改为使用5型磷酸二酯酶抑制剂（PDE-5Is）），两名患者能够自主勃起，一名患者最初有改善，但在第6个月时有所下降。未观察到副作用。干细胞疗法联合PLP似乎在勃起功能方面有一定改善，且短期内副作用最小。
